Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan for the first half of 2022, representing a year-on-year growth of 25%[1]. - The company's operating revenue for the first half of 2022 was CNY 18,353,747,808.66, representing a 39.34% increase compared to CNY 13,171,478,498.15 in the same period last year[28]. - The net profit attributable to shareholders decreased by 32.08% to CNY 3,729,017,351.47 from CNY 5,490,650,129.41 year-on-year[28]. - The net cash flow from operating activities turned negative at CNY -1,380,303,201.53, a decline of 121.14% compared to CNY 6,530,824,685.45 in the previous year[28]. - The company achieved operating revenue of 18.354 billion yuan, a year-on-year increase of 39.34%[46]. - The net profit attributable to the parent company was 3.729 billion yuan, a year-on-year decrease of 32.08%[46]. - The company reported a significant decline in the weighted average return on equity, dropping to 19.26% from 49.94% year-on-year[28]. - The company reported a total of 5.18 billion CNY in R&D investment for the first half of 2022, accounting for 31.08% of its self-developed product sales revenue[61]. Market Expansion and Product Development - User data indicates that the company has expanded its customer base, with a 30% increase in the number of vaccinations administered compared to the same period last year[2]. - The company has set a revenue guidance of 3 billion yuan for the full year 2022, reflecting an optimistic outlook based on current market trends[3]. - New product development includes the launch of a recombinant COVID-19 vaccine, which has shown a 90% efficacy rate in clinical trials[4]. - The company is actively pursuing market expansion, targeting a 15% increase in market share within the next year through enhanced marketing strategies[5]. - The company has allocated 200 million yuan for research and development in new vaccine technologies, aiming to diversify its product offerings[6]. - A strategic acquisition of a smaller biotech firm is in progress, which is expected to enhance the company's R&D capabilities and product pipeline[7]. - The company has established a robust sales network, resulting in a 20% increase in product sales in the first half of 2022[8]. - The company plans to invest in digital marketing initiatives to further boost customer engagement and sales performance[9]. - The company has developed a second-generation COVID-19 vaccine ZF2202 (Omicron-Delta chimeric vaccine) which shows good safety and efficacy, particularly with higher neutralizing antibody titers against the Omicron BA.4/5 variants[47]. - The company is focusing on mRNA technology development through its investment platform, Deep Trust Bio[39]. - The company has received conditional approval for its COVID-19 vaccine as a sequential booster, enhancing product offerings for public health[46]. - The company has 11 products on the market, including vaccines for meningitis, cervical cancer, pneumonia, and rotavirus[40]. Research and Development - The company is committed to a dual-driven development model of "technology + market" to ensure sustainable growth[45]. - The company emphasizes innovation and R&D, collaborating with leading research institutions to drive product development[42]. - The company has 28 self-developed projects, with 15 in clinical trial and registration stages, including a 23-valent pneumococcal polysaccharide vaccine currently under review for market approval[50]. - The company is actively conducting research on new COVID-19 vaccines using various technological approaches, including recombinant protein and mRNA, to enhance the ability to combat variants[47]. - The company’s recombinant COVID-19 protein vaccine (CHO cells) has been conditionally approved for market and is being used as a sequential booster[50]. - The company is focused on innovation and technological breakthroughs, with multiple products making clinical progress, including a freeze-dried human rabies vaccine and a quadrivalent influenza virus split vaccine[50]. - The company has established three major R&D and production bases to accelerate the development and registration of high-quality self-developed products[62]. - The company is conducting clinical trials for multiple vaccines, including the recombinant hepatitis B vaccine and the bivalent hand-foot-mouth disease vaccine, with plans to submit for clinical trials in 2022-2023[55]. - The company has a total of 647 R&D personnel, ensuring a robust talent pool for ongoing innovation[61]. Environmental Responsibility and Compliance - The company is classified as a key pollutant discharge unit, with specific emissions data reported[108]. - The company has actively engaged in investor relations activities, including multiple online meetings to discuss product development and operational status[98]. - The company has a commitment to regulatory compliance and environmental responsibility in its operations[108]. - The company reported a total wastewater discharge of 39.9 tons per year, with a chemical oxygen demand (COD) concentration of 38.0 mg/L[109]. - The total nitrogen discharge was 5.70 tons per year, with a concentration of 7.67 mg/L[109]. - The company achieved a total phosphorus discharge of 0.684 tons per year, with a concentration of 1.36 mg/L[109]. - The company has installed online monitoring equipment for wastewater discharge to ensure compliance with standards[111]. - The company operates three sets of air pollution control facilities, all of which meet discharge standards[111]. - The company reported a nitrogen oxide emission of 1.875 tons, with a concentration of 21 mg/Nm3[110]. - The company has established an emergency plan for sudden environmental incidents and filed it with the local ecological environment bureau[114]. - The company adheres to various environmental protection laws and regulations, ensuring strict control over wastewater, waste gas, and solid waste pollution sources[117]. - The company emphasizes ecological priority and green development, actively implementing national carbon peak and carbon neutrality strategies[117]. Social Responsibility - The company integrates social responsibility into its development, focusing on investor rights protection and participating in social welfare initiatives[118]. - In the first half of 2022, the company donated over 4 million yuan worth of vaccines and medicines to various regions for epidemic prevention[120]. - The company has committed 8 million yuan to the "China Women's Cervical Health Promotion Program" to support women's health initiatives[121]. - The company has actively participated in rural revitalization projects, donating a total of 105,000 yuan to local charities[121]. - The company has distributed a total cash dividend of 4.124 billion yuan since its listing, which is 2.8 times the amount raised during the IPO[119]. Corporate Governance - The company did not distribute cash dividends or bonus shares during the reporting period[102]. - The company has not experienced any changes in its board of directors or senior management during the reporting period[101]. - The company has not engaged in any related party transactions during the reporting period[130]. - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties during the reporting period[124]. - The half-year financial report has not been audited[126]. - The company has not issued any guarantees that violate regulations during the reporting period[125]. - The company’s major shareholders did not engage in any repurchase transactions during the reporting period[161].

Financial Performance - The company's operating revenue for 2021 was CNY 30,652,415,906.61, representing a 101.79% increase compared to CNY 15,190,366,231.21 in 2020[13]. - The net profit attributable to shareholders for 2021 was CNY 10,208,548,452.56, a 209.23% increase from CNY 3,301,326,830.15 in 2020[13]. - The basic earnings per share for 2021 was CNY 6.3803, up 209.23% from CNY 2.0633 in 2020[13]. - The total assets at the end of 2021 amounted to CNY 30,047,323,465.36, a 97.48% increase from CNY 15,215,241,753.29 at the end of 2020[13]. - The company reported a weighted average return on equity of 78.01% for 2021, an increase of 31.72% compared to 46.29% in 2020[13]. - The total revenue for 2021 reached approximately CNY 30.65 billion, representing a year-on-year increase of 101.79% from CNY 15.19 billion in 2020[56]. - Revenue from self-developed products amounted to CNY 9.70 billion, accounting for 31.64% of total revenue, with a remarkable growth of 707.61% compared to CNY 1.20 billion in 2020[56]. - The company reported a significant increase in sales volume, reaching 284,180,087 doses in 2021, up 864.95% from 29,450,087 doses in 2020[59]. - The company achieved a revenue of CNY 30,652,415,906.61 in 2021, representing a growth of 101.79% compared to the previous year[29]. Dividend Distribution - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares to all shareholders, based on a total of 1,600,000,000 shares[2]. - The company implemented a cash dividend policy, distributing 6.00 CNY per 10 shares, totaling 960 million CNY in cash dividends, which accounted for 100% of the total profit distribution[137]. - The company reported a total distributable profit of 12,291,924,179.08 CNY for the year 2021[137]. Research and Development - The company invested CNY 814 million in research and development during the reporting period[31]. - The company is investing heavily in R&D, with a budget allocation of 200 million RMB for the development of new vaccines and biopharmaceuticals[111]. - The company aims to enhance its vaccine research and development technology platform, targeting market potential and commercial development prospects[80]. - The company has multiple products in clinical trials, including three entering Phase III trials and two entering Phase I trials[30]. - The company has established three major R&D and production bases to accelerate the development and registration of high-quality products[42]. - The company has a strong pipeline of vaccines, including several in advanced clinical trial stages for various infectious diseases[32]. - The company has 11 products on the market, including vaccines for meningitis, cervical cancer, pneumonia, and rotavirus, addressing various infectious diseases[24]. Market Strategy and Operations - The company emphasizes a dual-driven development model of "technology + market" to support its growth strategy[23]. - The company operates under a "sales-driven production" model, aligning production with market demand[28]. - The company has established a professional marketing team of nearly 3,000 members, covering all 31 provinces and municipalities in China, and over 30,000 grassroots health service points[49]. - The company has a sales team of 2,817 members, which supports its operational plans but also presents management challenges[87]. - The company is actively pursuing WHO certification for its COVID-19 vaccine to improve accessibility and affordability, contributing to global immunization efforts[38]. - The company is focused on enhancing its brand influence and product competitiveness both domestically and internationally[85]. Compliance and Governance - The company emphasizes compliance and quality management, adhering to various laws and regulations to ensure sustainable operations[37]. - The company has a robust governance structure, with independent operational capabilities and no competition with its controlling shareholder[103]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations[100]. - The company has established a performance evaluation and incentive mechanism that aligns with its development status[97]. - The company published 4 periodic reports and 64 temporary reports during the reporting period, enhancing information transparency[97]. Environmental Compliance - The company is classified as a key pollutant discharge unit, indicating compliance with environmental regulations[148]. - The total chemical oxygen demand (COD) discharge was 7.7896 tons, with a concentration of 56.0 mg/L, well below the permitted limit[148]. - The company has implemented measures to ensure no significant defects in non-financial reporting[147]. - The company reported a significant reduction in emissions, with sulfur dioxide levels at <3 mg/Nm³ and nitrogen oxides at 28 mg/Nm³, adhering to the relevant environmental standards[151]. - The company has completed the low-nitrogen combustion transformation of two boilers, further reducing nitrogen oxide emissions[154]. Shareholder Information - The total shares held by the board members at the beginning of the period were 904,121,300, with a decrease of 4,691,000 shares during the period, resulting in an ending total of 899,430,300 shares[106]. - The largest shareholder, Jiang Rensheng, holds 50.11% of the shares, totaling 801,829,000, with a decrease of 3,691,000 shares during the reporting period[183]. - The number of shareholders holding ordinary shares at the end of the reporting period was 111,593, an increase from 89,963 at the end of the previous month[183]. - The company introduced strategic investors through share transfers to optimize its equity structure and reduce operational risks[180]. Employee Engagement and Development - The company emphasizes employee training and development, focusing on various training programs to enhance employee capabilities and align with business goals[133]. - The employee stock ownership plan involved 761 core employees holding a total of 16,150,000 shares, representing approximately 1.01% of the company's total equity[138]. - The company has a diverse workforce, with 1,137 production staff, 2,817 sales personnel, and 566 technical staff[131]. - The company has a total of 491 employees with master's degrees and 6 with doctoral degrees, indicating a strong educational background among its workforce[131]. Future Outlook - The company plans to expand its production capacity by 40% in the next two years to meet growing demand for its vaccines[158]. - The company aims to achieve carbon neutrality by 2030, implementing various green initiatives across its operations[159]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in innovative biotechnologies[111]. - Future outlook includes plans to expand into international markets, targeting a 15% increase in overseas sales by the end of the next fiscal year[111].

Financial Performance - The company's revenue for Q1 2022 reached ¥8,841,150,250.19, representing a 125.16% increase compared to ¥3,926,600,928.88 in the same period last year[1] - Net profit attributable to shareholders was ¥1,922,756,886.80, up 104.95% from ¥938,179,113.58 year-on-year[1] - Operating costs for Q1 2022 were ¥6,503,327,142.16, up from ¥2,756,078,603.71 in the same period last year, indicating an increase of about 136.5%[16] - Net profit for Q1 2022 was ¥1,922,756,886.80, compared to ¥938,179,113.58 in Q1 2021, reflecting a growth of approximately 104.3%[18] - The net profit margin for Q1 2022 was approximately 21.7%, compared to 23.9% in Q1 2021, indicating a slight decline in profitability[19] - Basic and diluted earnings per share for Q1 2022 were both ¥1.2017, up from ¥0.5864 in Q1 2021, reflecting an increase of approximately 104.3%[19] Cash Flow - The net cash flow from operating activities was -¥3,316,743,954.40, a significant decline of 2,814.44% compared to -¥113,803,717.67 in the previous year[1] - Total cash inflow from operating activities is 5,120,358,696.65 CNY, up from 2,651,288,724.02 CNY in the previous period[21] - Cash outflow from operating activities totals 8,437,102,651.05 CNY, compared to 2,765,092,441.69 CNY in the previous period, reflecting increased operational costs[21] - The net cash flow from financing activities increased by 169.74% to ¥1,412,329,711.67, attributed to a reduction in repayments of short-term loans[8] - Cash flow from financing activities shows a net inflow of 1,412,329,711.67 CNY, a substantial increase from 523,588,052.11 CNY in the previous period[21] - The company paid 1,199,335,368.80 CNY in taxes during the current period, significantly higher than 440,557,817.58 CNY in the previous period[21] - Cash and cash equivalents at the end of the period amount to 1,961,452,199.09 CNY, compared to 1,304,768,272.67 CNY at the end of the previous period[21] Assets and Liabilities - Total assets increased by 3.94% to ¥31,232,017,191.18 from ¥30,047,323,465.36 at the end of the previous year[2] - The company's total liabilities decreased to ¥11,652,047,392.55 at the end of Q1 2022 from ¥12,390,110,553.53 at the beginning of the year, a reduction of approximately 5.9%[16] - The company's equity attributable to shareholders rose by 10.89% to ¥19,579,969,798.63 from ¥17,657,212,911.83[2] - The total current assets increased to 25,573,666,529.61 from 24,753,780,404.17, indicating a growth in liquidity[14] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 30.41% to ¥16,781,140,653.65, driven by sustained sales growth[5] - The accounts receivable rose to 16,781,140,653.65 from 12,867,543,957.77, reflecting an increase in sales or credit extended to customers[14] - The inventory decreased to 6,624,995,699.96 from 7,385,396,274.99, suggesting improved inventory management or reduced production[14] Research and Development - Research and development expenses surged by 161.12% to ¥160,890,893.91, reflecting increased investment in R&D projects[7] - Research and development expenses for Q1 2022 amounted to ¥160,890,893.91, significantly higher than ¥61,614,846.81 in Q1 2021, representing an increase of about 160.5%[18] Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 89,963, with the top ten shareholders holding significant stakes, including Jiang Rensheng at 48.32%[9] - The total number of shares held by the top ten unrestricted shareholders includes Jiang Rensheng with 171,677,250 shares, indicating strong insider ownership[10] Product Issuance and Collaborations - The company reported a significant increase in the issuance of its products in Q1 2022, with the four-valent HPV vaccine issuance up by nearly 70% to 2.11 million doses, and the nine-valent HPV vaccine issuance up by 280% to 4.83 million doses[12] - The company continues its collaboration with Merck, focusing on increasing product supply to cover more eligible populations[12] Financial Management - The company is actively managing its financial assets, with a notable amount of 239,000,000 in other equity investments[14] - The company invested 409,610,155.15 CNY in fixed assets and intangible assets, down from 488,586,891.27 CNY in the previous period[21] - The company received 1,691,545,450.00 CNY in borrowings, slightly up from 1,593,398,716.00 CNY in the previous period[21] Exchange Rate Impact - The impact of exchange rate changes on cash and cash equivalents was -4,224,148.33 CNY, compared to a positive impact of 182,292.02 CNY in the previous period[21] Employee Engagement - The company has implemented an employee stock ownership plan, which was approved in early 2022, to enhance employee engagement and retention[11]

Group 1: Event Details - Chongqing Zhifei Biological Products Co., Ltd. will participate in the "2021 Investor Online Collective Reception Day" on November 25, 2021 [1] - The event will take place from 15:00 to 17:00, with an online platform available at http://rs.p5w.net [1] Group 2: Company Engagement - Senior management will engage with investors through online communication regarding corporate governance, development strategy, and operational status [1] - The company expresses gratitude for investor support and encourages active participation [1]

[Section 1 Important Notice, Table of Contents, and Definitions](index=2&type=section&id=Section%201%20Important%20Notice%2C%20Table%20of%20Contents%2C%20and%20Definitions) This section provides crucial disclaimers, outlines the report structure, and defines key terminology for clarity [Important Notice](index=2&type=section&id=Important%20Notice) The company's board and management guarantee report accuracy, cautioning investors on product R&D and sales risks, and disclosing the 2020 profit distribution plan - The company advises investors to pay attention to two core risks: **product R&D not meeting expectations** and **product sales not meeting expectations**[3](index=3&type=chunk)[4](index=4&type=chunk) - The company's 2020 profit distribution plan is: based on **1.6 billion shares**, a cash dividend of **5 yuan** (tax inclusive) will be distributed for every 10 shares[5](index=5&type=chunk) [Definitions](index=5&type=section&id=Definitions) This chapter defines key terms used in the report, including company entities, products, business models, industry terms, and regulatory bodies, providing a foundational understanding [Section 2 Company Profile and Key Financial Indicators](index=8&type=section&id=Section%202%20Company%20Profile%20and%20Key%20Financial%20Indicators) This section presents the company's fundamental information and a summary of its key financial performance metrics [Company Information](index=8&type=section&id=Company%20Information) This chapter provides the company's basic business information, including stock code, legal representative, addresses, contact details, and information disclosure channels - The company's stock abbreviation is "**Zhifei Biological**", and the stock code is **300122**[10](index=10&type=chunk) [Key Accounting Data and Financial Indicators](index=9&type=section&id=Key%20Accounting%20Data%20and%20Financial%20Indicators) The company achieved strong 2020 performance with operating revenue reaching **15.19 billion yuan** and net profit attributable to parent company at **3.301 billion yuan**, alongside significant growth in operating cash flow, total assets, and net assets Key Accounting Data and Financial Indicators | Indicator | 2020 | 2019 | Year-on-Year Change | | :--- | :--- | :--- | :--- | | **Operating Revenue (RMB)** | 15,190,366,231.21 | 10,587,318,311.60 | 43.48% | | **Net Profit Attributable to Shareholders of Listed Company (RMB)** | 3,301,326,830.15 | 2,366,438,733.29 | 39.51% | | **Net Cash Flow from Operating Activities (RMB)** | 3,496,688,940.12 | 1,366,993,830.88 | 155.79% | | **Basic Earnings Per Share (RMB/share)** | 2.0633 | 1.4790 | 39.51% | | **Weighted Average Return on Net Assets** | 46.29% | 47.67% | -1.38% | | **Total Assets (RMB)** | 15,215,241,753.29 | 10,942,422,443.88 | 39.05% | | **Net Assets Attributable to Shareholders of Listed Company (RMB)** | 8,248,664,459.27 | 5,747,337,629.12 | 43.52% | Quarterly Key Accounting Data | Quarter | Operating Revenue (RMB) | Net Profit Attributable to Shareholders of Listed Company (RMB) | | :--- | :--- | :--- | | **Q1** | 2,634,599,232.63 | 516,363,351.01 | | **Q2** | 4,359,123,952.00 | 988,185,044.15 | | **Q3** | 4,056,063,967.03 | 974,047,337.21 | | **Q4** | 4,140,579,079.55 | 822,731,097.78 | - During the reporting period, the company's total non-recurring gains and losses amounted to **-21.5786 million yuan**, primarily consisting of government subsidies, fair value changes in financial instruments, and other non-operating income and expenses[17](index=17&type=chunk)[18](index=18&type=chunk) [Section 3 Business Overview](index=12&type=section&id=Section%203%20Business%20Overview) This section outlines the company's core business activities, significant asset changes, and key competitive advantages [Main Business Activities During the Reporting Period](index=12&type=section&id=Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company is a bio-high-tech enterprise integrating vaccine R&D, production, sales, and import/export, operating under a 'technology + market' dual-driven model with a nationwide marketing network and a portfolio of proprietary and agency products - The company adopts a 'technology + market' dual-driven model, possessing a marketing network covering **31 provinces** nationwide and over **30,000 primary healthcare service points**[20](index=20&type=chunk) Key Products | Product Category | Trade Name | Purpose | | :--- | :--- | :--- | | **Proprietary Products** | Mengweike, Mengnakang, Xifeibei, Zhikeweide, Yika, Weika | Prevention of meningococcal meningitis, Haemophilus influenzae type b infection, COVID-19 infection, and tuberculosis diagnosis and adjuvant therapy | | **Agency Products (MSD)** | Gardasil, Gardasil 9, Rotateq, Pneumovax 23, Vaqta | Prevention of HPV (cervical cancer), rotavirus, pneumococcal, hepatitis A, and other diseases | - The global vaccine market is projected to grow from **$32.5 billion** in 2019 to **$56.1 billion** in 2026, indicating significant growth potential[23](index=23&type=chunk) [Significant Changes in Major Assets](index=14&type=section&id=Significant%20Changes%20in%20Major%20Assets) During the reporting period, the company's major assets, including accounts receivable, inventory, fixed assets, and development expenditures, significantly increased due to sales growth, increased agency product procurement, project completion, and capitalized R&D investments Major Asset Changes | Major Asset | Period-End vs. Period-Start Growth Rate | Primary Reason | | :--- | :--- | :--- | | **Accounts Receivable** | 49.30% | Continuous growth in sales revenue | | **Inventory** | 37.07% | Increased procurement of agency products as planned | | **Fixed Assets** | 42.76% | Completed construction-in-progress projects transferred to fixed assets | | **Development Expenditures** | 70.57% | Increased capitalized investment in R&D projects | [Core Competitiveness Analysis](index=14&type=section&id=Core%20Competitiveness%20Analysis) The company's core competitiveness stems from its industry-leading R&D capabilities, mature nationwide marketing network, and standardized operational management, ensuring product quality and sales performance - The company's R&D investment in 2020 reached **481 million yuan**, with **414 R&D personnel** and **27 ongoing projects**, forming multiple vaccine product matrices for tuberculosis, rabies, pneumonia, and meningitis[26](index=26&type=chunk)[27](index=27&type=chunk) - The company's marketing network covers **31 provinces**, over **300 prefectures**, over **2,600 districts/counties**, and over **30,000 primary healthcare service points** nationwide, effectively ensuring product sales[32](index=32&type=chunk) - The company has established a strict quality control system, maintaining a **100% batch release qualification rate** for proprietary products since their first launch in 2008[33](index=33&type=chunk) [Section 4 Management Discussion and Analysis](index=19&type=section&id=Section%204%20Management%20Discussion%20and%20Analysis) This section provides a detailed review of the company's operational performance, product development, and future strategic outlook [I. Overview](index=19&type=section&id=I.%20Overview) In 2020, the company achieved significant growth despite the pandemic, driven by strong revenue and net profit increases, strategic R&D investments, successful product launches, expanded market promotion, and forward-looking investments in new health technologies - The **recombinant COVID-19 vaccine (CHO cell)** developed by the company in collaboration with the Institute of Microbiology, Chinese Academy of Sciences, initiated clinical trials in June 2020 and was included in emergency use in March 2021[36](index=36&type=chunk) - R&D investment in 2020 reached **481 million yuan**, a year-on-year increase of **85.61%**, accounting for **40.02%** of proprietary product revenue[39](index=39&type=chunk) - The company renewed its agency agreement with MSD, further clarifying vaccine product procurement plans until the end of June 2023; as of the end of the reporting period, over **25 million doses** of HPV vaccine had been cumulatively released[42](index=42&type=chunk) - The company strategically invested in Shenzhen Shenxin Biotechnology Co., Ltd. to establish an **mRNA technology platform**[44](index=44&type=chunk) [Product R&D and Batch Release Status](index=22&type=section&id=Product%20R%26D%20and%20Batch%20Release%20Status) As of the reporting period end, the company had **27 proprietary R&D projects** with key approvals for EC diagnostic reagent, recombinant COVID-19, and inactivated rotavirus vaccines, while both proprietary and agency vaccine batch releases saw significant increases - The company has a total of **27 proprietary R&D projects**, with Mycobacterium bovis vaccine (for tuberculosis-infected population) in the production application stage, and multiple products including 15-valent pneumococcal conjugate vaccine and recombinant COVID-19 vaccine in Phase III clinical trials[46](index=46&type=chunk)[47](index=47&type=chunk) Proprietary Product Batch Release Status | Proprietary Product | 2020 Batch Release Volume (doses) | 2019 Batch Release Volume (doses) | Growth Rate | | :--- | :--- | :--- | :--- | | **ACYW Meningococcal Polysaccharide Vaccine** | 6,062,370 | 754,797 | 703.18% | | **AC Conjugate Vaccine** | 4,404,060 | 669,205 | 558.10% | Agency Product Batch Release Status | Agency Product (MSD) | 2020 Batch Release Volume (doses) | 2019 Batch Release Volume (doses) | Growth Rate | | :--- | :--- | :--- | :--- | | **Quadrivalent HPV Vaccine** | 7,219,462 | 5,543,719 | 30.23% | | **Nonavalent HPV Vaccine** | 5,066,376 | 3,324,173 | 52.41% | [II. Main Business Analysis](index=26&type=section&id=II.%20Main%20Business%20Analysis) In 2020, the company's main business revenue reached **15.19 billion yuan**, primarily driven by **agency non-immunization program vaccines** contributing **13.955 billion yuan**, with East China as the largest market, and overall sales, production, and inventory volumes increasing significantly Main Business Revenue Composition | Revenue Component | 2020 Revenue (RMB) | Share of Total Revenue | Year-on-Year Change | | :--- | :--- | :--- | :--- | | **Agency Products - Non-Immunization Program Vaccines** | 13,955,381,554.82 | 91.86% | 51.88% | | **Proprietary Products - Non-Immunization Program Vaccines** | 1,197,987,988.40 | 7.89% | -9.50% | | **Proprietary Products - Therapeutic Biological Products** | 2,768,852.43 | 0.02% | -79.05% | Main Business by Region | Region | 2020 Revenue (RMB) | Share of Total Revenue | | :--- | :--- | :--- | | **East China** | 5,191,826,815.43 | 34.18% | | **South China** | 2,436,024,991.83 | 16.04% | | **Central China** | 2,397,183,366.85 | 15.78% | - The top five customers accounted for **8.63%** of the company's total annual sales, while the top five suppliers (primarily MSD) accounted for **92.78%** of total annual procurement, indicating a high dependency on core suppliers[71](index=71&type=chunk)[73](index=73&type=chunk) - Financial expenses and R&D expenses significantly increased by **75.35%** and **76.73%** year-on-year respectively, primarily due to increased interest expenses from higher short-term borrowings and increased R&D investments[75](index=75&type=chunk) [IX. Company's Future Development Outlook](index=34&type=section&id=IX.%20Company%27s%20Future%20Development%20Outlook) The company plans to focus on its core vaccine business while expanding into biopharmaceuticals, advancing its R&D pipeline, ensuring product quality, enhancing market strategies, and optimizing governance, while also addressing identified risks such as policy changes, bad debts, talent management, adverse reactions, and vaccine hesitancy - The company's strategic core is to steadily advance R&D, ensure product clinical and registration processes, and strengthen the construction of **Zhirui Biopharmaceutical Industrial Park** to expand into therapeutic macromolecular drug fields such as **oncology** and **metabolic diseases**[91](index=91&type=chunk) - The main risks faced by the company include: **changes in industry regulatory policies**, **accounts receivable bad debt risk** due to expanding sales scale, **talent management risk** from sales team expansion, **vaccine adverse reaction risk**, and public "**vaccine hesitancy**" sentiment[93](index=93&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk) [Section 5 Significant Matters](index=38&type=section&id=Section%205%20Significant%20Matters) This section details the company's profit distribution plan, significant contracts, and employee stock ownership plan [Profit Distribution and Capital Reserve Conversion to Share Capital](index=38&type=section&id=Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20to%20Share%20Capital) The company's 2020 profit distribution plan proposes a cash dividend of **5 yuan** per **10 shares** based on **1.6 billion shares**, totaling **800 million yuan**, representing **24.23%** of net profit attributable to the parent company, consistent with prior years Cash Dividends for the Past Three Years | Dividend Year | Cash Dividend Amount (RMB) | Ratio of Net Profit Attributable to Ordinary Shareholders of Listed Company in Consolidated Financial Statements | | :--- | :--- | :--- | | **2020** | 800,000,000.00 | 24.23% | | **2019** | 800,000,000.00 | 33.81% | | **2018** | 800,000,000.00 | 55.12% | [Significant Contracts and Their Performance](index=44&type=section&id=Significant%20Contracts%20and%20Their%20Performance) During the reporting period, the company's significant contracts with MSD were performed normally, with **HPV vaccine** procurement reaching **8.33 billion yuan** in 2020, and a new agreement signed in December 2020 to adjust and renew procurement for five agency products - On December 22, 2020, the company signed a new agreement with MSD, renewing and adjusting the basic procurement amounts for **HPV vaccine**, **pentavalent rotavirus vaccine**, **23-valent pneumococcal vaccine**, and **inactivated hepatitis A vaccine**[119](index=119&type=chunk) [Employee Stock Ownership Plan](index=42&type=section&id=Employee%20Stock%20Ownership%20Plan) The company's second employee stock ownership plan completed stock purchases in 2019, acquiring **16,150,000 shares** at an average price of **41.2753 yuan/share**, with its lock-up period expiring on July 29, 2020, and **8,901,164 shares** still held as of the reporting period end - The lock-up period for the company's second phase employee stock ownership plan expired on July 29, 2020, and as of the end of the reporting period, the plan still held **8,901,164 shares**[114](index=114&type=chunk) [Section 6 Share Changes and Shareholder Information](index=48&type=section&id=Section%206%20Share%20Changes%20and%20Shareholder%20Information) This section details changes in the company's share capital and provides an overview of its shareholder structure [Share Change Status](index=48&type=section&id=Share%20Change%20Status) During the reporting period, the company's total share capital remained at **1.6 billion shares**, with restricted shares decreasing by **24.6 million shares** due to executive lock-up share unlocking, shifting the proportion of restricted to unrestricted shares - During the reporting period, the company's total share capital of **1,600,000,000 shares** remained unchanged, with share changes primarily due to the annual unlocking of executive restricted shares[128](index=128&type=chunk) [Shareholders and Actual Controller Information](index=50&type=section&id=Shareholders%20and%20Actual%20Controller%20Information) As of the reporting period end, the company had **94,851 shareholders**, with Mr. Jiang Rensheng as the controlling shareholder holding **50.35%**, and Hong Kong Securities Clearing Company Limited as the fourth largest shareholder with **3.23%** - The company's controlling shareholder and actual controller is Jiang Rensheng, with a shareholding ratio of **50.35%** at the end of the reporting period[134](index=134&type=chunk)[140](index=140&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shareholding Percentage | Number of Shares Held at Period End | | :--- | :--- | :--- | | **Jiang Rensheng** | 50.35% | 805,520,000 | | **Jiang Lingfeng** | 5.40% | 86,400,000 | | **Liu Tieying** | 3.81% | 61,000,000 | | **Hong Kong Securities Clearing Company Limited** | 3.23% | 51,624,330 | | **Wu Guanjiang** | 3.02% | 48,280,000 | [Section 9 Directors, Supervisors, Senior Management, and Employees](index=56&type=section&id=Section%209%20Directors%2C%20Supervisors%2C%20Senior%20Management%2C%20and%20Employees) This section provides details on the shareholding changes and remuneration of the company's directors, supervisors, and senior management, as well as overall employee information [Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=56&type=section&id=Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) During the reporting period, Chairman Jiang Rensheng reduced his shareholding by **27,720,000 shares** and Deputy General Manager Jiang Xisheng by **1,000,000 shares**, while the total remuneration paid to the **18 directors, supervisors, and senior management** in 2020 was **12.9265 million yuan** - Chairman Jiang Rensheng reduced his shareholding by **27,720,000 shares** during the reporting period, with his shareholding at period-end being **805,520,000 shares**[145](index=145&type=chunk) - The company has a total of **18 directors, supervisors, and senior management**, with the total actual remuneration paid in 2020 amounting to **12.9265 million yuan**[154](index=154&type=chunk)[155](index=155&type=chunk)[156](index=156&type=chunk) [Company Employee Information](index=62&type=section&id=Company%20Employee%20Information) As of the reporting period end, the company had **3,380 employees**, with sales personnel comprising the largest group at **1,905**, and over **70%** of employees holding a bachelor's degree or higher, indicating high personnel quality Employee Professional Composition | Professional Composition | Number of Employees | | :--- | :--- | | **Production Personnel** | 763 | | **Sales Personnel** | 1,905 | | **Technical Personnel** | 414 | | **Financial Personnel** | 62 | | **Administrative Personnel** | 236 | | **Total** | 3,380 | [Section 10 Corporate Governance](index=64&type=section&id=Section%2010%20Corporate%20Governance) This section provides an overview of the company's corporate governance structure and its adherence to regulatory standards [Basic Status of Corporate Governance](index=64&type=section&id=Basic%20Status%20of%20Corporate%20Governance) The company maintains a compliant and independent corporate governance structure with clear responsibilities, effective checks and balances, and active board and supervisory committee functions, including performance-linked executive incentives, ensuring legal operations and financial integrity - The actual status of the company's corporate governance **complies with the requirements** of normative documents such as the 'Guidelines for Corporate Governance of Listed Companies', with no significant discrepancies[161](index=161&type=chunk)[162](index=162&type=chunk) - The company maintains **independence from its controlling shareholder** in terms of business, personnel, assets, organization, and finance, possessing independent and complete business operations and autonomous management capabilities[163](index=163&type=chunk)[164](index=164&type=chunk)[165](index=165&type=chunk)[166](index=166&type=chunk) - The four special committees under the company's board of directors—**Audit, Nomination, Remuneration and Appraisal, and Strategy**—all performed their duties normally during the reporting period[171](index=171&type=chunk) [Section 12 Financial Report](index=75&type=section&id=Section%2012%20Financial%20Report) This section presents the company's audited financial statements and key consolidated financial data [I. Audit Report](index=75&type=section&id=I.%20Audit%20Report) ShineWing Certified Public Accountants issued a standard **unqualified audit opinion** on the company's 2020 financial statements, confirming fair presentation in accordance with accounting standards, with key audit matters focusing on inventory impairment, accounts receivable bad debt provisions, and revenue recognition - The auditing firm is ShineWing Certified Public Accountants (Special General Partnership), which issued a **standard unqualified audit opinion**[188](index=188&type=chunk)[189](index=189&type=chunk) - Key audit matters include: - **Inventory impairment provisions**: Due to high book value of inventory (accounting for **22.38%** of total assets) and significant increase - **Accounts receivable bad debt provisions**: Due to high accounts receivable balance (accounting for **43.54%** of total assets), bad debt risk has a significant impact on the financial statements - **Revenue recognition**: Due to operating revenue being a key performance indicator and increasing by **43.48%** year-on-year, there is an inherent risk of management manipulating revenue recognition timing[191](index=191&type=chunk)[192](index=192&type=chunk) [Key Consolidated Financial Statement Data](index=78&type=section&id=Key%20Consolidated%20Financial%20Statement%20Data) As of 2020 year-end, the company reported **15.215 billion yuan** in total assets, **6.967 billion yuan** in total liabilities, and **8.249 billion yuan** in equity attributable to the parent, with **15.19 billion yuan** in operating revenue and **3.301 billion yuan** in net profit for the year Key Consolidated Balance Sheet Data | Balance Sheet Item (Consolidated) | 2020 Year-End (RMB) | 2019 Year-End (RMB) | | :--- | :--- | :--- | | **Total Assets** | 15,215,241,753.29 | 10,942,422,443.88 | | **Total Liabilities** | 6,966,577,294.02 | 5,195,084,814.76 | | **Equity Attributable to Parent Company Owners** | 8,248,664,459.27 | 5,747,337,629.12 | Key Consolidated Income Statement Data | Income Statement Item (Consolidated) | 2020 Annual (RMB) | 2019 Annual (RMB) | | :--- | :--- | :--- | | **Total Operating Revenue** | 15,190,366,231.21 | 10,587,318,311.60 | | **Total Operating Costs** | 11,179,799,938.20 | 7,709,979,663.15 | | **Net Profit** | 3,301,326,830.15 | 2,366,438,733.29 | Key Consolidated Cash Flow Statement Data | Cash Flow Statement Item (Consolidated) | 2020 Annual (RMB) | 2019 Annual (RMB) | | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | 3,496,688,940.12 | 1,366,993,830.88 | | **Net Cash Flow from Investing Activities** | -896,881,545.26 | -622,733,368.64 | | **Net Cash Flow from Financing Activities** | -2,113,588,340.56 | -392,796,755.93 |